Laurens V. Beerepoot

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

Salo Ooft, Fleur Weeber, Krijn K. Dijkstra et al. · Science Translational Medicine · 2019 · 769 citations

Gastrointestinal Oncology, Pdo Test, Medicine +9

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 738 citations

Neuro-oncology, Oncology, Single-agent Bevacizumab +10

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.

Manabu Kuroki, Emile E. Voest, Shiro Amano et al. · Journal of Clinical Investigation · 1996 · 420 citations · Full text

Redox Biology, Tumor Biology, Oxidative Stress +19

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

Kristy J. Gotink, Henk J. Broxterman, Mariëtte Labots et al. · Clinical Cancer Research · 2011 · 335 citations · Full text